SB 745 Summary

• Establishes a statewide investigational new drug application to conduct clinical trials using marijuana for five qualifying conditions: neuropathic pain, muscle spasms from multiple sclerosis or paraplegia, chemotherapy-induced nausea/vomiting, cancer or HIV/AIDS-related weight loss, and chronic pain when other treatments fail.

• Allows physicians licensed in Oklahoma to serve as principal investigators if approved by federal entities and registered with the Oklahoma State Bureau of Narcotics and Dangerous Drugs Control; permits board-certified subinvestigators at academic medical centers.

• Provides immunity from criminal and civil penalties for persons complying with the act's provisions, excluding clinical trial participants using marijuana outside authorized purposes.

• Requires clinical trials to use only research-grade marijuana approved by the National Institutes of Health, adhere to institutional review board standards, and conclude by December 31, 2019.

• Mandates the State Commissioner of Health submit a report by December 31, 2019 summarizing clinical trial findings and medical efficacy; effective date is November 1, 2017.